Infant samples | Infection route | Homo-/heterogeneous population ratio | References | ||
---|---|---|---|---|---|
Nature | Collection time* | Amplified envregion | |||
PBMCs | 2 to 4Â months | V3 and V4-V5 | Unspecified | 3/0 | [61] |
PBMCs | Unspecified | V3 and V4-V5 | Unspecified | 4/0 | [68] |
PBMCs and serum | 0 to 4Â months | V3 | 1Â IU, 9 unknown | 8 (1Â IU)/2 | [69] |
Serum | At birth | V3 | 1Â IU | 1/0 | [70] |
PBMCs | 0 to 12.5Â months | V3 | 1Â IU, 4 unknown | 2/3 (1Â IU) | [71] |
PBMCs | 2Â days to 7Â weeks | V1-V2-C2 | Unspecified | 1/2 | [72] |
PBMCs | 1Â week to 34Â months | V3 | Unspecified | 7/0 | [73] |
PBMCs | 5Â days to 1.5Â months | V3 | Probably 1 PN, 3Â IU | 1 (PN)/3 (IU) | [74] |
PBMCs and plasma | 2 to 40Â days | C2-V3 | Unspecified | 3/1 | [75] |
PBMCs | 1Â month | V3 | Unspecified | 13/4 | [76] |
Plasma | 48Â hours or 2 to 6Â weeks | V3-V5 | 9 PN, 14Â IU | 17 (7 PN, 10Â IU)/6 (2 PN, 4Â IU) | [77] |
PBMCs | 0 or 2 to 6Â months | C2-V4 | 3 PN or early PP, 1Â IU | 3 (2 PN, 1Â IU)/1 | [78] |
PBMCs | 0 or 6Â weeks | V1-V4 | 7 PN or early PP, 6Â IU | 6 (2Â IU, 4 PN)/7 (4Â IU, 3 PN) | [79] |
PBMCs | 48Â hours or 2 to 6Â weeks | V3-V5 | 7 PN, 14Â IU | 15 (5 PN, 10Â IU)/6 (2 PN, 4Â IU) | [80] |
PBMCs or plasma | 6Â weeks | V1-V5 | 8 PN or early PP, 1Â IU, 3 BF | 11/1 (PN) | [81] |
PBMCs or cord blood | 0 or 6 to 15Â months | V1-V3 | 3 PP, 1Â IU | 4/0 | [82] |
PBMCs | 4 to 18Â months | V1-V5 | Unspecified | 0/3 | [83] |
Plasma | 0 or 6Â weeks | V1-V2 | 23 PN, 25Â IU | 20 (6 PN, 14Â IU)/28 (17 PN, 11Â IU) | [84] |
Plasma | 48Â hours or 6Â weeks | V1-V5 | 11 PN, 6Â IU | 14 (9 PN, 5Â IU)/3 (2 PN, 1Â IU) | [85] |
PBMCs | 2 to 4Â months | V1-V5 | 6 PN or early PP | 5/1 | [86] |
Plasma | 30 to 66Â days | V1-V5 | 5 PN | 3/2 | [87] |
Plasma | 0 or 6Â weeks | V1-V5 | 9 PN or early PP, 10Â IU | 13 (5 PN, 8Â IU)/6 (4 PN, 2Â IU) | [88] |
Plasma | 3 or 6Â months | complete env | 2 PP | 2/0 | [89] |
 |  |  |  | total: 156/235 |  |